高级检索
当前位置: 首页 > 详情页

Pediatric hematopoietic stem cell transplantation in China: Data and trends during 1998-2012

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Navy General Hospital, Beijing, China [2]Shanghai Children’s Medical Center, Shanghai, China, [3]Beijing Children’s Hospital, Beijing, China, [4]Second Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, [5]Prince of Wales Hospital, Hong Kong, China, [6]West China Second University Hospital of Sichuan University, Chengdu, China, [7]Guangzhou Women and Children Medical Center, Guangzhou, China, [8]Beijing Tongren Hospital, Beijing, China, [9]Children’s Hospital of Chongqing Medical University, Chongqing, China, [10]Zhe Jiang University School of Medicine Children Hospital, Hangzhou, China, [11]Soochow University Affiliated Children’s Hospital, Suzhou, China, [12]Capital Institute of Pediatics, Beijing, China, [13]Wuhan Union Hospital, Wuhan, China
出处:
ISSN:

关键词: hematopoietic stem cell transplantation cord blood survival graft-versus-host disease

摘要:
The success of treating a wide variety of pediatric diseases with HSCT, hematologic malignancies in particular, has resulted in an increased number of long-term survivors. This study is the first large-scale, multicentre report that describes the evolution of pediatric HSCTs in China during the period of 1998-2012. Of all 1052 patients, 266 cases were treated with autologous HSCs and 786 used allogeneic HSCs. The disease indications for HSCTs mainly included leukemias, lymphoma, solid tumors, and non-malignant disorders. The total number of HSCTs, especially unrelated donor transplants, appeared to be increasing year by year. For patients with neuroblastoma, the therapeutic efficacy seemed to be poor, with a five-yr OS and DFS rate of 34.5 +/- 14.3% and 20.7 +/- 9.6%, respectively. In contrast, the survival of patients with SAA was prominently improved, and their five-yr OS and DFS rates were 82.8 +/- 4% and 80.7 +/- 4.1%, respectively. Patients who received cord blood transplants had a lower incidence of acute GVHD than that of PB and/or BM transplants from unrelated donors. This report offers us a valuable resource for evaluating the changes in HSCTs in China over the past 14yr.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类 | 4 区 医学
小类 | 4 区 儿科 4 区 移植
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 儿科 4 区 移植
JCR分区:
出版当年[2015]版:
Q3 PEDIATRICS Q4 TRANSPLANTATION
最新[2023]版:
Q3 PEDIATRICS Q3 TRANSPLANTATION

影响因子: 最新[2023版] 最新五年平均 出版当年[2015版] 出版当年五年平均 出版前一年[2014版] 出版后一年[2016版]

第一作者:
第一作者机构: [1]Navy General Hospital, Beijing, China
共同第一作者:
通讯作者:
通讯机构: [1]Navy General Hospital, Beijing, China [*1]Department of Pediatrics, Navy General Hospital, No. 6, Fucheng Road, Beijing 100048, China
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Donor peritoneal-derived cells can attenuate graft-versus-host disease after MHC-incompatible bone marrow transplantation in mice [2]Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China [3]Correction: Hematopoietic stem cell transplantation activity in China 2022-2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group [4]Role of Gut Microbiota and Oxidative Stress in the Progression of Transplant-Related Complications following Hematopoietic Stem Cell Transplantation [5]Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients with CMML [6]The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China [7]Autologous hematopoietic stem cell transplantation followed by interleukin-2 for adult acute myeloid leukemia patients with favorable or intermediate risk after complete remission [8]Hematopoietic stem cell transplantation activity in China 2020-2021 during the SARS-CoV-2 pandemic: a report from the Chinese Blood and Marrow Transplantation Registry Group [9]Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission [10]Hematopoietic stem cell transplantation activity in China 2022-2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group

资源点击量:52808 今日访问量:0 总访问量:4561 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号